GH secretagogue
CJC-1295 (no DAC)
Not approved; no published human trialsUser reports onlyMod GRF 1-29Modified GRF (1-29)CJC no DAC
A modified version of the first 29 amino acids of GHRH, the hormone that tells the pituitary to release growth hormone. The changes make it last longer than natural GHRH, but it's still short-acting (minutes). It's usually paired with ipamorelin. There are no published human trials of this exact compound.
- Canada
- Not authorized; named in Health Canada's 2026 warning
- United States
- Not approved
Download profile Opens in Vialchemy on your iPhone, where it's added to your Library as your own.
Not medical advice — talk to your doctor before making medical decisions.
At a glance
- Class
- GH secretagogue (GHRH analog)
- Mechanism
- Signals the pituitary to release growth hormone in a pulse
- Evidence
- No published human trials (related GHRH drugs are studied)
- Canada
- Not authorized
- Us
- Not approved
- Half Life
- About 30 minutes
- Routes
- SubQ
- Common Side Effects
- Flushing, headache, water retention, tingling hands
- Key Cautions
- Raised blood sugar; avoid with cancer history; WADA prohibited
What the research says
Does it work in people?
It's expected to raise GH like other GHRH analogs (sermorelin, tesamorelin), but there are no published human trials of this compound, and no evidence it improves body composition or sleep in healthy adults.
With ipamorelin?
The most common pairing. The two work on different receptors and the combination is meant to give a larger GH pulse. No published human trials of the pair.
With a GLP-1?
GH raises blood sugar, GLP-1s lower it. Not studied together; check fasting glucose and A1C.
Not the same as CJC-1295 with DAC
"No DAC" lasts minutes; "with DAC" lasts about a week. Check which one your vial is before you calculate anything.
Common side effects and cautions
- Water retention, tingling or numb hands, joint aches and headache are the usual GH-related effects.
- Raised growth hormone and IGF-1 can raise blood sugar and lower insulin sensitivity. Worth watching if you're also on a GLP-1 or have prediabetes.
- Flushing, light-headedness or a rush of hunger right after injection are commonly reported.
- Long-term raised IGF-1 is linked in studies to cancer growth, so people with active cancer or a history of it are usually told to avoid GH-raising compounds.
- Prohibited in sport (WADA S2) if you're drug-tested.
Get medical care if
- Redness, heat, swelling or pus at a site that spreads or comes with fever
- Hives, swelling of the face or throat, or trouble breathing (call 911)
Buying and quality
- Not authorized by Health Canada. Products sold online as "research use only" are illegal to sell for human use in Canada, and the label doesn't change that.
- Health Canada warns these products may contain too much, too little or none of the peptide, plus contaminants like endotoxins, solvents, heavy metals or bacteria.
- A certificate of analysis (COA) from the seller isn't independent proof. A 98% purity result still leaves 2% unidentified.
- If you use it anyway: one clean needle per injection, sterile technique, label and date every vial, and stop if a site gets hot, red and spreading.
Dose calculator
Doses are set with your prescriber. This converts a dose you already have into what to draw; it doesn't recommend one. Check every number against your syringe and your vial's label.
Doses left in the vial
A blend vial
Not medical advice — talk to your doctor before making medical decisions.
Sources
Researched 2026-10-27. Trial results and approval status change.
General education, not medical advice. Nothing here is a dose recommendation. Doses, schedules and changes are set with a prescriber.